Death Associated Protein kinase (DAP kinase) a novel calmodulin-dependent serine/threonine kinase was ®rst identi®ed as a positive mediator of programmed cell death. Loss of DAP kinase expression was ®rst demonstrated in highly metastatic cells, whilst reexpression of the protein resulted in delayed local tumour growth and a decreased incidence of metastasis. Although loss of DAP kinase expression has been reported in several cell lines derived from human malignancies the mechanisms responsible have not been de®ned. In this study we have examined 32 sporadic pituitary tumours for expression of the DAP kinase protein and transcript. In addition, we examined the methylation and deletion status of the DAP kinase CpG island as possible mechanisms for the inactivation of the DAP kinase gene. Eleven of 32 (34%) tumours had undetectable DAP kinase expression, by Western blot and/or RT ± PCR analysis. Loss of DAP kinase expression was signi®cantly (P=0.004) associated with invasive tumours (10 of 17; 59%) compared to their noninvasive (1 of 15; 7%) counterparts. Of 11 tumours that failed to express DAP kinase, ®ve (45%) showed de novo methylation of the CpG island contained within the promoter region, while four (36%) had evidence of homozygous deletion of this region. Statistical analysis showed that loss of DAP kinase expression was signi®cantly (P=50.001) associated with methylation or deletion of the DAP kinase CpG island. With two exceptions, none of the remaining tumours or ®ve histologically normal post-mortem pituitaries examined had evidence of methylation or deletion within this region. To our knowledge this is the ®rst report that describes two mutually exclusive mechanisms associated with loss of DAP kinase gene expression. In addition, we also show that loss of the DAP kinase protein and associated genetic aberrations preferentially segregates with tumours that show an invasive phenotype.
Introduction
An increasing number of cell death genes have been implicated in the active process of programmed cell death (PCD), which is an essential mechanism in normal development and in the maintenance of multicellular organisms (Wyllie et al., 1980; Ra, 1992; Schwartz and Osborne, 1993) . PCD may be initiated through speci®c extracellular signals, including tumour necrosis factor-a (TNF-a), Interferon-g (IFN-g) and transforming growth factor-b (TGF-b) that trigger cell cycle arrest and/or apoptosis. (Itoh et al., 1991; Lin and Chou, 1992; Novelli et al., 1994; Laster et al., 1998) . Aberrations in this process have been described in numerous diseases and pathologies, where a decrease in the apoptotic rate has been observed in several dierent cancers in contrast to an abnormal increase in the rate of this process in neurodegenerative diseases (Evan and Littlewood, 1998) .
The Death Associated Protein kinase (DAP kinase) gene, located on chromosome 9q34.1 (Feinstein et al., 1995a) , was initially isolated as a calcium/calmodulindependent positive mediator of IFN-g induced apoptosis and is associated with the cell cytoskeleton (Deiss et al., 1995; Feinstein and Kimichi, 1995b; . The deduced amino acid structure of the 160 KDa DAP kinase protein contains a kinase domain composed of 11 sub-domains typical of serine/threonine kinases. Adjacent to this region are eight ankryn repeats, followed by two P-loop motifs. In addition, within the 3' end of the protein is a death domain with homology to other proteins involved in the PCD pathways including the TNF receptor (p55-R) and Fas/Apo 1 (Feinstein and Kimichi, 1995b) .
Studies have suggested that inhibition of the PCD pathway plays a critical role in the multi-step aetiology of tumorigenesis (Martin et al., 1994) . The p53 and Bcl-2 genes, as positive and negative regulators of apoptosis respectively, have been implicated in the PCD pathway and tumorigenesis. The p53 gene is the most commonly altered tumour suppressor to be identi®ed in human malignancies; its loss or inactivation may lead to the inhibition of cell death. In the context of inactivation a very recent report has established a role for DAP kinase in the activation of a p19 ARF /p53 checkpoint (Raveh et al., 2001) . Thus, loss of DAP kinase may provide a mechanism that leads to inactivation of this critical apoptotic pathway in tumorigenesis.
The role of the DAP kinase gene as a tumour suppressor was demonstrated in highly metastic murine lung carcinomas, which failed to express the DAP kinase protein, in contrast to their non-invasive counterpart (Inbal et al., 1997) . Re-expression of DAP kinase in these highly metastic tumours inhibited their ability to form lung metastases after intravenous injection into syngeneic mice (Inbal et al., 1997) . Conversely, in vivo selection of lung lesions, after prior injection of low-metastic Lewis carcinoma cells or of DAP kinase transfectants into mice, was associated with loss of DAP kinase expression in surviving tumour cells (Inbal et al., 1997) . Loss of DAP kinase expression has been shown in a number of human malignancies including primary bladder and renal cell carcinomas, and cell lines established from breast carcinomas (Kissill et al., 1997) . In addition, Kissill et al. (1997) also showed that it was possible to re-express the DAP kinase protein from previously DAP kinase negative bladder and B-cell carcinoma cell lines using the nucleotide analogue 5-aza 2'-deoxycytidine. While these ®ndings would suggest that loss of DAP kinase expression in primary tumours might be linked to epigenetic mechanisms of gene silencing, no studies have described the simultaneous characterization of expression and aberrations within the DAP kinase gene.
Since the CpG islands of tumour suppressor genes (TSG) are normally unmethylated they are potential targets for aberrant methylation during tumorigenesis, which may inhibit their transcription. Pituitary tumours are no exception and we recently described methylation associated gene silencing for both the p16 (Simpson et al., 1999a) and RBI genes (Simpson et al., 2000) , that showed tumour subtype speci®city (Simpson et al., 2001) . Aberrant methylation of the DAP kinase CpG island has been described in thyroid lymphoma (Nakatsuka et al., 2000) , primary pancreatic adenocarcinomas (Ueki et al., 2000) and the primary tumours and serum DNA from patients with non-small cell lung cancer, and head and neck tumours (Esteller et al., 1999; Sanchez-Cespedes et al., 2000; Tang et al., 2000) . However, these studies did not describe the consequent eect on cognate protein expression.
To further elucidate the role of DAP kinase in pituitary tumorigenesis we have examined DAP kinase expression status, by Western blot and RT ± PCR analysis, in 32 tumours of pituitary origin, which have been further subdivided into non-invasive and invasive cohorts. To identify mechanisms responsible for or associated with loss of DAP kinase expression we have examined the methylation and deletion status of the CpG island associated with the DAP kinase gene.
Results

DAP kinase expression in pituitary adenomas
All thirty-two tumours were examined for the expression status of the DAP kinase protein and/or mRNA using Western Blot and RT ± PCR techniques respectively. Eleven (one non-invasive; 10 invasive) of 32 (34%) tumours examined failed to express DAP kinase protein and/or transcript. In all cases the absence of DAP kinase protein was coincident with loss of DAP kinase transcript. A single tumour (no. 16), which had insucient tumour material available for Western blot analysis, also failed to express the DAP kinase transcript. Figure 1 shows the DAP kinase expression status of representative tumours as assessed by Western blot analysis, while Figure 2 shows DAP kinase transcript expression status in these tumours. The absence of DAP kinase protein/transcript was signi®-cantly associated (P=0.004) with invasive tumours (10 of 17; 59%) compared to their non-invasive counterparts (one of 15; 7%). All histologically normal postmortem pituitaries examined showed expression of both the DAP kinase protein and transcript ( Table 1) .
Methylation of the DAP kinase CpG island
The CpG island contained within the DAP kinase gene was examined for methylation, using the MS ± PCR technique, in all 32 tumours and ®ve histologically normal post-mortem pituitaries. As a positive control we included an in vitro methylated control (see Materials and methods) in each modi®cation and subsequent ampli®cation.
Of the 32 tumours examined 7 (22%) showed de novo methylation of the DAP kinase CpG island. Five of these seven (71%) (one non-invasive; four invasive) methylated tumours failed to express detectable levels of DAP kinase protein and transcript, and two tumours (one non-invasive; one invasive), which showed methylation of the DAP kinase CpG island expressed DAP kinase protein and mRNA. Statistical analysis showed that methylation of the DAP kinase gene is signi®cantly associated with loss of DAP kinase expression (P=0.004). In a further four tumours, which failed to express DAP kinase protein or transcript, we were unable to generate a PCR product using either DAP kinase oligonucleotides speci®c for methylated or unmethylated DNA after bisulphite conversion. In addition, all matched bloods and histological normal post-mortem pituitaries were unmethylated as assessed by the MS ± PCR technique. Figure 3 shows representative analysis using the MS ± PCR technique while Table 1 summarizes the methylation status of the DAP kinase gene in all tumours and normal pituitaries tissues studied. We next con®rmed that methylation status was not in¯uenced by the ®xation process. Converted DNA, derived from fresh frozen material (see Materials and methods) that represented the methylated tumours and post-mortem pituitaries described above was subject to MS ± PCR. In all seven methylated tumours and the post-mortem pituitaries (see above) the methylation status of the DAP kinase gene was concordant with those obtained from the slide-extracted material.
Multiplex and sequence analysis of the DAP kinase CpG island
In four tumours we were unable to successfully amplify a PCR product using oligonucleotide sets speci®c for methylated or unmethylated DNA (see above), we therefore examined the deletion status of the DAP kinase CpG island in these tumours, together with the total tumour cohort and all histologically normal postmortem pituitaries.
Using multiplex PCR, the four tumours which failed to express DAP kinase protein and/or mRNA, showed homozygous deletion of the DAP kinase CpG island. In addition, it was possible to amplify this region from the remaining tumours, irrespective of their expression, or methylation status, and all histologically normal post-mortem pituitaries examined ( Figure 4 and Table  1) .
Two tumours that were unmethylated failed to express DAP kinase however, multiplex analysis Figure 3 Representative examples of MS ± PCR analysis of the DAP kinase CpG island in pituitary tumours and histologically normal post-mortem pituitary. All DNA samples were sodium bisulphite treated prior to MS ± PCR analysis. Modi®ed DNA samples were subjected to PCR analysis with oligonucleotides speci®c for unmethylated (U) or methylated (M) DNA. A PCR product is generated from in vitro methylated genomic DNA (IVD) with the oligonucleotide set speci®c for methylated but not unmethylated DNA. The absence of methylation in histologically normal post-mortem pituitary is demonstrated by the presence of a PCR product generated by the oligonucleotides speci®c for unmethylated DNA. Representative PCR products corresponding to methylated (nos. T13 and T27) and unmethylated (no. T11 and T12) tumours are also shown. No methylation was found in any of the matched blood DNA samples examined (data not shown Nakatsuka et al., 2000) have shown detectable levels of DAP kinase promoter methylation, using the MS ± PCR technique, in thyroid lymphoma, primary tumours and the serum DNA from patients with pancreatic and non-small cell lung cancers however, these studies did not examine the expression status of the DAP kinase gene. In this study two tumours showed methylation of the DAP kinase promoter region that was not associated with loss of DAP kinase expression. To our knowledge this is the ®rst report that directly assesses the association between methylation of the DAP kinase gene and expression however, in other primary tumour types, for example gliomas, it has been suggested that partial methylation is not consistently associated with the presence or absence of p16 mRNA (Costello et al., 1996) . In this context a number of reports have suggested that complete gene silencing is dependant on the density and extent of methylation, which may vary with the developmental stage of the tumour (for review see Zingg and Jones, 1997; Baylin et al., 1998) Since the MS ± PCR technique detects methylation of speci®c residues it may not, in all cases, accurately re¯ect either the density or extent of methylation. By signi®cantly increasing the PCR cycle number in the MS ± PCR analysis we were able to detect a band corresponding to unmethylated alleles, suggesting heterogeneous methylation within the tumour cell population at the CpG sites examined (data not Figure 4 Multiplex analysis of the DAP kinase promoter. Representative examples of three tumours (nos. T16, T23 and T25) and matched blood DNA samples, analysed for homozygous deletion of the DAP kinase promoter region. Tumour (T) and matched blood (B) DNA was subjected to PCR ampli®cation using DAP kinase promoter speci®c oligonucleotides (see Table  2 ). In addition the housekeeping gene GAPDH was also coampli®ed as an internal control for DNA integrity. The GAPDH and DAP kinase amplicons are indicated in each case. Homozygous deletion is demonstrated by the absence of one of the expected DAP kinase PCR products compared to the matched blood DNA sample. Tumours nos. T16 and T23 showed homozygous deletion of the DAP kinase CpG island, whilst at least one functional allele remained intact in tumour no. 25 Figure 5 Southern blot analysis of the DAP kinase gene. Four tumours (12, 15, 23 and 24) were available for Southern blot analysis. In samples from normal pituitary and tumours (12 and 15) that expressed DAP kinase transcript and protein, a single fragment (*5.5 kb) was resolved. In tumours (23 and 24) that failed to express DAP kinase a smaller fragment of approximately 5 kb was evident. In these cases Southern blot analysis con®rms the promoter deletion detected by multiplex PCR. To con®rm DNA integrity re-probing showed the presence of the b-actin control in all of the tissues examined shown). In human pituitary derived tumours we recently showed a signi®cant association between methylation of the p16 gene and loss of p16 protein expression however, a small number of tumours, that were methylated, expressed p16 protein (Simpson et al., 1999a) . Although these studies (DAP kinase and p16) cannot exclude expression of these genes from in®ltrating non-neoplastic cells these analyses were performed on micro-dissected tumour material thereby minimizing the contribution of normal`contaminating' cells.
A recent study (Ueki et al., 2000) showed methylation of the DAP kinase CpG island in pancreatic tumours in addition, these authors report a proportion of normal pancreatic tissue also harboured DAP kinase methylation. We found no evidence for DAP kinase CpG island methylation in normal pituitary, although the number of specimens available was limited. While we cannot positively exclude this phenomenon in normal pituitary, our ®ndings in this tissue, together with the highly infrequent methylation in non-invasive tumours (one of 15) would suggest this to be unlikely. Indeed, analysis of a further 20 pituitary adenomas showed a similar frequency of DAP kinase CpG island methylation. However, in these cases there was insucient tumour available for investigation of DAP kinase expression or deletion status.
Two tumours failed to express the DAP kinase protein and transcript, although this was not associated with methylation of the CpG island or deletion within this region. However, as detailed previously these ®ndings may simple re¯ect heterogeneous methylation within the CpG island. Since the genomic sequence of DAP kinase has not been described it was not possible to further analyse this gene for micro-deletions or mutation. However, within the CpG region examined we were unable to detect point mutation(s) by direct sequence analysis. In those tumours shown to harbour deletion within this region it was not possible to determine the exact extent of the deletion. Southern blot analysis identi®ed a single, DAP kinase speci®c fragment of approximately 5.5 Kb, in histologically normal post-mortem pituitary and two tumours which expressed DAP kinase. However, in two of four tumours shown to harbour deletion by multiplex analysis sucient DNA was available for Southern blot analysis. In these cases a smaller, DAP kinase speci®c fragment was identi®ed. In addition, mapping of the chromosome 9q34.1 region using ®ve highly polymorphic microsatellite markers showed no loss of heterozygosity (LOH) at these loci (data not shown). Taken together, these data suggest that the identi®ed deletion within the CpG island is discrete and con®ned to the DAP kinase gene.
A recent report suggests that loss of DAP kinase expression may provide a link between a compromised apoptotic pathway and subsequent metastasis (Inbal et al., 1997) . In studies by our own group LOH at known or putative TSG loci appear to be more frequent in invasive pituitary tumours and pituitary carcinomas in comparison to their non-invasive counterparts (Boggild et al., 1994; Bates et al., 1997; Simpson et al., 1999b) , while losses on chromosome 9p and methylation mediated silencing of the p16 gene appear to be early changes (Simpson et al., 1999a) . Thus, in these regions showing LOH, associated with the transition from non-invasive to invasive adenomas, as yet unidenti®ed genes may play a role in the suppression of apoptosis and metastastic or invasive potential. However, we now demonstrate that loss of DAP kinase expression associated with methylation or deletion of its promoter region is signi®cantly associated with invasive pituitary tumours compared to their non-invasive counterparts. A recent study (Sanchez-Cespedes et al., 2000) has shown a signi®cant association between methylation of the DAP kinase promoter and lymph node involvement and advanced disease state. However, pituitary carcinomas and their metastases are rare, although two tumours within the invasive cohort were carcinomas. Interestingly, in both cases we identi®ed loss of DAP kinase expression associated with methylation of the DAP kinase CpG island. Only a single non-invasive tumour failed to express detectable levels of the DAP kinase protein.
However, this may identify a tumour that if left unchecked would have a predilection toward an invasive and/or metastic phenotype. The infrequent transition of invasive pituitary tumours to the metastic phenotype, despite loss of DAP kinase expression may simply re¯ect that other co-operating aberrations are necessary to complete this ®nal transition. Equally, these ®ndings may suggest that invasive pituitary tumours as the corollary to lymph node invasion seen in other tumour types.
Although no causal relationship has been shown between methylation of the DAP kinase promoter region and an absence of DAP kinase protein Kissill et al. (1997) showed that after treatment with a cytosine nucleotide analogue DAP kinase expression was restored in cell lines previously shown not to express the DAP kinase protein. These authors' data suggests that methylation of the DAP kinase CpG island may be a possible mechanism for the silencing of the DAP kinase gene. However, failure to re-express DAP kinase in some cell lines, after treatment with the demethylating agent suggested mechanisms other than, or perhaps in addition to methylation may be responsible for loss of gene expression (Kissill et al., 1997) . Ideally we would have wished to treat pituitary tumour cells with a de-methylating agent to establish a causal link between methylation and gene silencing. However, pituitary tumours of human origin are notoriously dicult to propagate in vitro and the cytostatic/cytotoxic eects of these nucleotide analogues precluded these types of analyses.
To our knowledge this is the ®rst report describing likely mechanisms responsible for loss of DAP kinase expression in human neuroendocrine tumours of pituitary origin. Furthermore, in those tumours which failed to express DAP kinase we suggest two mutually exclusive mechanisms: (i) methylation of the CpG island; or (ii) homozygous deletion of the CpG island, which may be responsible for the silencing of the DAP kinase gene. In addition, we also show that loss of DAP kinase expression is signi®cantly associated with more biologically aggressive tumours than their noninvasive counterparts. Since several studies have shown re-activation of methylated tumour suppressor genes using nucleotide analogues (reviewed in Jones, 1996; Zingg and Jones, 1997; Baylin et al., 1998 ) the reexpression of DAP kinase in sporadic pituitary tumours may provide a potential target for therapeutic intervention in the reactivation of this pathway.
Materials and methods
Patient material
Thirty-two sporadic human pituitary tumours with matched blood samples were obtained from patients who had undergone hypophysectomy. Tumour tissues were collected retrospectively following standard histological assessment. Prior to DNA analysis tumours were de®ned as non-invasive or invasive on the basis of CT and/or MRI reports and graded according to criteria based on a modi®ed Hardy's classi®cation (Hardy, 1979) as previously described (Boggild et al., 1994; Bates et al., 1997) . Grade 1 tumours were microadenomas (51 cm diameter) and grade 2 tumours consisted of enclosed macroadenomas (41 cm diameter) with or without suprasellar extension. Both grade 1 and 2 tumours were de®ned as non-invasive. Grade 3 tumours were locally invasive with evidence of bony destruction and tumour within the sphenoid and/or cavernous sinus. Grade 4 tumours demonstrate CNS/extracranial spread with or without metastases. Grade 3 and 4 tumours were considered to be invasive. The tumour cohort examined consisted of 14 nonfunctioning pituitary tumours and 18 clinically functional tumours (15 non-invasive; 17 invasive). In addition, ®ve histologically normal post-mortem pituitaries obtained within 12 h of death. Approximately one-third of each of the postmortem pituitaries and primary tumours were ®xed and embedded as described below and the remainder stored without ®xation at 7208C.
DNA preparation from formalin fixed and embedded tumours and normal pituitaries
Ten 5-mm sections were taken from tumour and post-mortem pituitary which had been formalin ®xed and paran embedded. A single section was subjected to H and E staining, allowing tumour identi®cation and subsequent microdissection from the remaining unstained sections. DNA was extracted by prolonged (3 days) proteinase K (0.2 mg/ml) digestion in 50-mM Tris-HCL (pH 8.5), 1-mM EDTA, and 0.5% Tween 20. Samples were heated to 998C for 10 min and subjected to brief centrifugation. Supernatants were removed and stored at 48C. Leukocyte DNA was extracted from matched blood samples using commercially available reagents (Nucleon 1; Scotlab, Strathclyde, UK).
RT ± PCR analysis
Sucient tissue was available from 30 tumours and ®ve histologically normal post-mortem pituitaries for RNA extraction as previously described (Chomczynski and Sacchi, 1987) . A total of 2 ± 5 mg of total RNA was heated to 658C for 10 min in the presence of 0.2 mg random hexamer oligonucleotide, and then snap cooled on ice in a total volume of 12 ml. In a ®nal volume of 20 ml, the reactioncontained 200 mM of dATP, dGTP, dTTP, and dCTP, 1X ®rst strand buer mix (GibcoBRL, Life Technologies Ltd, UK), 10 mM dithiothreitol. The reaction was heated at 428C for 2 min prior to the addition of 2 units of reverse transcriptase (Superscript II Rnase H-Reverse Transcriptase; GibcoBRL, Life Technologies Ltd, UK). The reaction mix was incubated for a further 1 h at 428C. The reaction was stopped by heating to 958C for 5 min, and cDNA's stored at 7208C.
PCR ampli®cation of the resulting cDNA was achieved with oligonucleotides speci®c for the DAP kinase gene designed according to the published sequence (GenBank Accession no. X76104). PCR ampli®cation was limited to 30 cycles to ensure ampli®cation in the exponential phase. To con®rm cDNA integrity a portion of the housekeeping gene HPRT was co-ampli®ed from tumour and histologically normal post-mortem pituitary. Oligonucleotide sequences are shown in Table 2 .
Western blot analysis
Twenty-seven tumours and ®ve histologically normal postmortem pituitaries were subjected to Western blot analysis for DAP kinase protein. Samples were suspended in 0.5 ml lysis buer (50 mM Tris-HCL (pH 8.0), 0.5 mM phenymethylsulphonyl¯uoride (PMSF), 0.02% sodium azide, 0.1% sodium dodecyl sulphate (SDS), 1% Nonident P-40, 0.5% sodium deoxycholate and 1.5 mM aprotinin). After centrifugation the supernatants were removed and stored at 7708C until required.
Equivalent amounts of protein (20 mg) were subjected to SDS ± PAGE. Gels were soaked in 16transfer buer (48 mM Tris base, 39 mM glycine, 0.037% SDS, 20% methanol) and protein was transferred to HyBond C+nitro-cellulose membrane (Amersham Ltd, UK). After blotting the membranes were blocked with 5% skimmed milk powder in PBS for 1 h. A monoclonal antibody directed against the human DAP kinase protein (Sigma Ltd UK; clone DAP kinase-55) was diluted 1/250 in PBS and incubated for 1 h at room temperature. Signals were developed using an HRPconjugated sheep anti-mouse secondary antibody (DAKO Ltd, UK) and chemiluminescence according to the manufacture's protocol (Pierce and Warriner, Chester, UK). Blots were stripped and re-probed with an anti-vinculin antibody (Sigma Chemical Co). In all cases the molecular weight of the DAP kinase and vinculin protein was con®rmed against known molecular weight standards and a SKN cell lysate as directed by the supplier (Aniti Bioreagents Inc, Cambridge Bioscience, Cambridge, UK).
Sodium bisulphite modification
DNA (200 ng) was denatured with NaOH (®nal concentration 0.2 M) in a total volume of 10 ml for 10 min at 378C. 1 mg of salmon sperm DNA was added as a carrier prior to denaturation. Sodium bisulphite solution (250 ml; 0.5 M hydroquinone, 2.2 M sodium bisulphite) at pH 5, freshly prepared, was added and mixed. To ensure full denaturation and deamination, DNA samples were denatured at 958C for 5 min and further incubated at 558C for 55 min, this was repeated for a total of six cycles (Grigg, 1996) . DNA samples were then puri®ed using the Wizard puri®cation resin according to the manufacturer's protocol (Promega, UK) and eluted in 50 ml of water. Modi®cation was completed by desulphonation with NaOH (®nal concentration 0.3 M) for 15 min at 378C. DNA was ethanol precipitated and re-suspended in 10 ml of water. Samples were stored at 48C.
DAP kinase methylation status by MS ± PCR
The DAP kinase gene has a region in the ®rst 525 bp of its cDNA sequence that quali®es as a CpG island (Katzenellenbogen et al., 1999) . Oligonucleotides speci®c for the CpG island of the DAP kinase gene were as previously described (Esteller et al., 1999; Ueki et al., 2000; Sanchez-Cespedes et al., 2000; Tang et al., 2000) . Oligonucleotide sequences are shown in Table 2 . To con®rm PCR ampli®cation of methylated DAP kinase CpG island sequence after modi®ca-tion we methylated genomic DNA in vitro with the CpG methylase enzyme Sss I. This DNA was then subjected to sodium bisulphite modi®cation as described above and served as a positive control.
PCR reactions contained oligonucleotide sets speci®c for methylated or unmethylated DAP kinase CpG island (2 pmol of each primer), 1.5 mM MgCl 2 , and 200 ng of modi®ed template DNA. Reactions were hot started (968C for 5mins) before the addition of 1 unit Taq DNA polymerase and 200 mM each of dATP, dGTP, dTTP and dCTP. PCR was carried out for 30 cycles (558C for 30 s, 728C for 30 s and 948C for 1 min).
Products were run on 8% non-denaturing polyacrylamide gels, ®xed in 10% methylated spirit/0.5% acetic acid for 6 min and then incubated in 0.1% aqueous silver nitrate for 15 min. Following two brief washes in distilled water, products were visualized by development in 1.5% sodium hydroxide/0.1% formaldehyde.
Multiplex analysis of the DAP kinase CpG island
Tumour and matched blood DNA were subjected to PCR ampli®cation of the DAP kinase CpG island region previously examined for methylation (Esteller et al., 1999; Ueki et al., 2000; Sanchez-Cespedes et al., 2000; Tang et al., 2000) , using speci®c oligonucleotides. In addition, the housekeeping gene GAPDH was co-ampli®ed as an internal control for DNA integrity (Table 2 ). Tumour and matched blood DNA were serially diluted prior to PCR ampli®cation. PCR ampli®cation was carried out as described above, however, PCR cycles were limited to 26 to ensure ampli®cation remained in the exponential phase. PCR products were run on 8% non-denaturing polyacrylamide gels and products visualized as described above. On the resulting gel, a tumour lane was chosen in which the intensity of the GAPDH signal was similar to that of GAPDH signal in the matched blood DNA. Homozygous deletion of the region of the DAP kinase CpG island examined was con®rmed by the absence of the expected DAP kinase PCR product in the tumour DNA (see Figure 4 ).
Sequence analysis of the DAP kinase promoter region
To investigate the possibility of inactivating mutations, two tumours, which were unmethylated and failed to express detectable levels of DAP kinase, were subjected to sequence analysis. Oligonucleotides speci®c for the DAP kinase gene (used for multiplex analysis of the identical region; see Table  2 ) were used for the ampli®cation. PCR ampli®cation was achieved at an annealing temperature of 588C. PCR conditions were as described above. PCR amplicons were subjected to cycle sequencing reactions according to the manufacturers protocol (BigDye TM Terminator cycle sequencing, PE Applied Biosystems, Warrington, UK) using both sense and anti-sense PCR oligonucleotides. Cycle sequencing products were subjected to capillary electrophoresis using an automatic sequencer (ABI Prism 310 Genetic Analyser, PE Applied Biosystems, Warrington, UK). Sequencing data was analysed using Sequencing Analysis V3.0 (ABI Prism, PE Applied Biosystems, Warrington, UK).
Southern blot analysis of the DAP kinase gene
Southern blot analysis was performed as previously described . Southern blots were prepared from restriction enzyme digests of 10 mg of tumour and histologically normal post-mortem pituitary DNA, subjected to agarose gel (0.5%) electrophoresis and transferred to nylon membrane (Schleicher & Schuell, Dassel, Germany) . Blots were hybridized with a random-primed [a-32 -P]-dCTP labelled probe for 16 h at 608C and washed under stringent conditions. Autoradiographs were developed after 2 ± 7 days. To detect the DAP kinase gene we used a 724 bp fragment (encompassing nucleotides 4351 ± 5074; GenBank accession no. NM004938) generated from cDNA. A range of restriction enzymes, alone and in combination, were initially used prior to Southern blotting. After restriction digest with EcoRI a single fragment (*5.5 kb) was detected (from blood and post-mortem pituitary) using the cDNA probe described above. Thus, subsequent analysis of DAP kinase deletion status in histologically normal post-mortem pituitary and tumour DNA was carried out using EcoRI digested DNA. After stripping, blots were re-hybridized with a genomic probe to b-actin to control for DNA loading and integrity as previously described .
Statistical analysis
The Chi-square analysis of the relationship between DAP kinase expression status, DAP kinase methylation/deletion and clinicopathological features was performed using Stata statistical package (version 5, Stata Corp, Texas). Signi®cance was taken at the 5% level.
